WASOG Clinical Trial Endpoint Task Force: Executive Summary.

ABSTRACT: Over the past few years, an increased number of clinical trials have been performed evaluating specific therapies for pulmonary and cardiac sarcoidosis. However, a lack of consensus remains for appropriate clinical trial endpoints. In 2024, the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) established a clinical trial endpoint Task Force to update the 2011 WASOG Task Force. This initiative was spearheaded by five sarcoidosis specialists (RPB, EEL, DAC, MAJ, AUW) and enlisted a total of 55 stakeholders, including 37 health care providers, 14 industry representatives, and 4 patients. In March 2025, 46 stakeholders participated in a one-day meeting which included twenty focused talks regarding clinical trial endpoints for pulmonary and cardiac sarcoidosis trials. A

SUBMITTER: Baughman RP 

PROVIDER: S-EPMC12536850 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature